HRP20100293T1 - Formulacije za benzimidazolil piridil etere - Google Patents
Formulacije za benzimidazolil piridil etere Download PDFInfo
- Publication number
- HRP20100293T1 HRP20100293T1 HR20100293T HRP20100293T HRP20100293T1 HR P20100293 T1 HRP20100293 T1 HR P20100293T1 HR 20100293 T HR20100293 T HR 20100293T HR P20100293 T HRP20100293 T HR P20100293T HR P20100293 T1 HRP20100293 T1 HR P20100293T1
- Authority
- HR
- Croatia
- Prior art keywords
- formulation
- mixture
- formulation according
- compound
- formula
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 42
- 238000009472 formulation Methods 0.000 title claims abstract 29
- SYLABBNLHCTJEF-UHFFFAOYSA-N 2-pyridin-2-yloxy-1h-benzimidazole Chemical class N=1C2=CC=CC=C2NC=1OC1=CC=CC=N1 SYLABBNLHCTJEF-UHFFFAOYSA-N 0.000 title 1
- 239000002904 solvent Substances 0.000 claims abstract 13
- 150000001875 compounds Chemical class 0.000 claims abstract 8
- 239000004615 ingredient Substances 0.000 claims abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 239000003995 emulsifying agent Substances 0.000 claims abstract 4
- 239000007787 solid Substances 0.000 claims abstract 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical group CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83271506P | 2006-07-21 | 2006-07-21 | |
| PCT/US2007/016469 WO2008011154A2 (en) | 2006-07-21 | 2007-07-20 | Formulations for benzimidazolyl pyridyl ethers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100293T1 true HRP20100293T1 (hr) | 2010-06-30 |
Family
ID=38819293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100293T HRP20100293T1 (hr) | 2006-07-21 | 2010-05-25 | Formulacije za benzimidazolil piridil etere |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8455662B2 (pt) |
| EP (1) | EP2046292B1 (pt) |
| JP (1) | JP2009544617A (pt) |
| KR (1) | KR20090033904A (pt) |
| CN (1) | CN101516335B (pt) |
| AT (1) | ATE459338T1 (pt) |
| AU (1) | AU2007275634B2 (pt) |
| BR (1) | BRPI0715423A2 (pt) |
| CA (1) | CA2657346A1 (pt) |
| CY (1) | CY1110037T1 (pt) |
| DE (1) | DE602007005139D1 (pt) |
| DK (1) | DK2046292T3 (pt) |
| ES (1) | ES2340631T3 (pt) |
| HR (1) | HRP20100293T1 (pt) |
| MX (1) | MX2009000770A (pt) |
| PL (1) | PL2046292T3 (pt) |
| PT (1) | PT2046292E (pt) |
| RU (2) | RU2452469C2 (pt) |
| SI (1) | SI2046292T1 (pt) |
| WO (1) | WO2008011154A2 (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20070335A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| PE20080766A1 (es) * | 2006-08-30 | 2008-06-15 | Novartis Ag | Sales de benzimidazolil piridil eteres y formulaciones que las contienen |
| CN101679372A (zh) * | 2007-03-02 | 2010-03-24 | 诺瓦提斯公司 | Raf激酶抑制剂的固体形式 |
| US20100087481A1 (en) * | 2008-10-03 | 2010-04-08 | Lee Kathleen M | Oral pharmaceutical formulations for antidiabetic compounds |
| JO3434B1 (ar) * | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| MX340819B (es) | 2010-06-29 | 2016-07-26 | Poniard Pharmaceuticals Inc * | Formulacion oral de inhibidores de quinasa. |
| EP2588476A4 (en) | 2010-06-30 | 2014-07-23 | Verastem Inc | SYNTHESIS AND USE OF KINASE INHIBITORS |
| CN102336740B (zh) * | 2010-07-27 | 2013-07-24 | 中国科学院上海药物研究所 | 一类咪唑类化合物及其用途 |
| CN103301067B (zh) * | 2012-03-15 | 2018-09-11 | 苏州泽璟生物制药有限公司 | 一种改善吸收性能的固体分散体及其制备 |
| WO2014153509A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| US10561627B2 (en) * | 2014-12-31 | 2020-02-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| CA3058806A1 (en) | 2017-04-03 | 2018-10-11 | Coherus Biosciences Inc. | Ppar.gamma. agonist for treatment of progressive supranuclear palsy |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| KR0179401B1 (ko) * | 1994-02-28 | 1999-03-20 | 송택선 | 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체 |
| US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US6037136A (en) | 1994-10-24 | 2000-03-14 | Cold Spring Harbor Laboratory | Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto |
| US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| AU728701B2 (en) | 1996-05-23 | 2001-01-18 | Applied Research Systems Ars Holding N.V. | Compounds that inhibit the binding of Raf-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same |
| AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US6204467B1 (en) | 1998-03-24 | 2001-03-20 | Ford Global Technologies, Inc. | Method and apparatus for resistive welding |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US6391683B1 (en) * | 2000-06-21 | 2002-05-21 | Siliconware Precision Industries Co., Ltd. | Flip-chip semiconductor package structure and process for fabricating the same |
| AU2001285349A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The University Of Arkansas | Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2 |
| AU6294501A (en) * | 2000-09-20 | 2002-04-02 | Rtp Pharma Inc | Spray drying process and compositions of fenofibrate |
| US20040131670A1 (en) * | 2001-04-17 | 2004-07-08 | Ping Gao | Pellicle-resistant gelatin capsule |
| US20030198666A1 (en) * | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| SI1499311T1 (sl) * | 2002-03-29 | 2010-03-31 | Novartis Vaccines & Diagnostic | Substituirani benzazoli in njihova uporaba kot inhibitorji Raf kinaze |
| US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| US20050082192A1 (en) * | 2002-06-17 | 2005-04-21 | Eric Smarr | End cap support for jumbo rolls of material |
| US7846959B2 (en) * | 2004-05-07 | 2010-12-07 | Exelixis, Inc. | Raf modulators and methods of use |
| PE20070335A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| US20100231394A1 (en) * | 2009-03-11 | 2010-09-16 | Bobby Eugene Finchum | Carbon monoxide detection and dissipation apparatus |
-
2007
- 2007-07-20 AT AT07810647T patent/ATE459338T1/de active
- 2007-07-20 DE DE602007005139T patent/DE602007005139D1/de active Active
- 2007-07-20 PL PL07810647T patent/PL2046292T3/pl unknown
- 2007-07-20 RU RU2009105819/15A patent/RU2452469C2/ru not_active IP Right Cessation
- 2007-07-20 PT PT07810647T patent/PT2046292E/pt unknown
- 2007-07-20 EP EP07810647A patent/EP2046292B1/en active Active
- 2007-07-20 WO PCT/US2007/016469 patent/WO2008011154A2/en active Application Filing
- 2007-07-20 BR BRPI0715423-2A patent/BRPI0715423A2/pt not_active IP Right Cessation
- 2007-07-20 JP JP2009520854A patent/JP2009544617A/ja not_active Ceased
- 2007-07-20 MX MX2009000770A patent/MX2009000770A/es active IP Right Grant
- 2007-07-20 DK DK07810647.3T patent/DK2046292T3/da active
- 2007-07-20 AU AU2007275634A patent/AU2007275634B2/en not_active Ceased
- 2007-07-20 CN CN200780035017.9A patent/CN101516335B/zh not_active Expired - Fee Related
- 2007-07-20 CA CA002657346A patent/CA2657346A1/en not_active Abandoned
- 2007-07-20 SI SI200730219T patent/SI2046292T1/sl unknown
- 2007-07-20 ES ES07810647T patent/ES2340631T3/es active Active
- 2007-07-20 US US12/374,383 patent/US8455662B2/en not_active Expired - Fee Related
- 2007-07-20 KR KR1020097003547A patent/KR20090033904A/ko not_active Application Discontinuation
-
2010
- 2010-05-14 CY CY20101100427T patent/CY1110037T1/el unknown
- 2010-05-25 HR HR20100293T patent/HRP20100293T1/hr unknown
-
2012
- 2012-02-28 RU RU2012107218/15A patent/RU2012107218A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2046292B1 (en) | 2010-03-03 |
| AU2007275634A1 (en) | 2008-01-24 |
| US8455662B2 (en) | 2013-06-04 |
| BRPI0715423A2 (pt) | 2013-07-02 |
| SI2046292T1 (sl) | 2010-06-30 |
| CN101516335A (zh) | 2009-08-26 |
| EP2046292A2 (en) | 2009-04-15 |
| RU2452469C2 (ru) | 2012-06-10 |
| PL2046292T3 (pl) | 2010-08-31 |
| ES2340631T3 (es) | 2010-06-07 |
| WO2008011154A3 (en) | 2008-06-26 |
| ATE459338T1 (de) | 2010-03-15 |
| MX2009000770A (es) | 2009-01-28 |
| JP2009544617A (ja) | 2009-12-17 |
| RU2009105819A (ru) | 2010-08-27 |
| RU2012107218A (ru) | 2013-09-10 |
| DE602007005139D1 (de) | 2010-04-15 |
| PT2046292E (pt) | 2010-04-26 |
| CN101516335B (zh) | 2014-01-08 |
| WO2008011154A2 (en) | 2008-01-24 |
| CY1110037T1 (el) | 2015-01-14 |
| KR20090033904A (ko) | 2009-04-06 |
| CA2657346A1 (en) | 2008-01-24 |
| DK2046292T3 (da) | 2010-06-07 |
| AU2007275634B2 (en) | 2011-01-20 |
| US20100040677A1 (en) | 2010-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100293T1 (hr) | Formulacije za benzimidazolil piridil etere | |
| HRP20140097T1 (hr) | Farmaceutski sastav jakog hcv-inhibitora za oralnu primjenu | |
| Bromberg et al. | Effects of polyether-modified poly (acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers | |
| TWI625131B (zh) | 膏劑及其製造方法 | |
| ES2531646T3 (es) | Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno | |
| RS54152B1 (en) | PHARMACEUTICAL DOSAGE FORMS WITH CONTROLLED RELEASE | |
| PL1713446T3 (pl) | Nielamelarne trójskładnikowe kompozycje lipidów | |
| EP2100661A3 (en) | Cyclopropene complex compositions | |
| PE20070377A1 (es) | Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol | |
| Bajaj et al. | Self-nanoemulsifying drug delivery system of cefpodoxime proxetil containing tocopherol polyethylene glycol succinate | |
| CN107106577B (zh) | 泥罨剂 | |
| Guleri et al. | Formulation and evaluation of topical gel of aceclofenac | |
| ATE522204T1 (de) | Beschichtete pellets | |
| JP2017503866A (ja) | デュタステリドを含む自己乳化型薬物送達システムのための組成物 | |
| JP2014503479A5 (ja) | アリピプラゾール組成物 | |
| TW200942275A (en) | Aqueous patch that contains ketoprofen lysine salt | |
| KR20130059322A (ko) | 케토프로펜 함유 수성 첩부제 | |
| PH12014502609B1 (en) | Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug | |
| CN107148269A (zh) | 含有s‑氟比洛芬的外用剂组合物 | |
| JPWO2010093020A1 (ja) | 硬カプセル | |
| WO2007022105A3 (en) | Stable pharmaceutical compositions, processes for making the same, and methods of their use | |
| JP2015168630A (ja) | カプセル充填組成物 | |
| KR102066108B1 (ko) | 페닐링을 가지는 2종 화합물을 포함하는 화장료 조성물 | |
| WO2004108163A1 (ja) | 低帯電性粉末の製造方法 | |
| JP2014227400A (ja) | 抗しわ組成物及び化粧料 |